APREA THERAPEUTICS, INC.

(APRE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

RBC Trims Price Target on Aprea Therapeutics to $4 From $5, Maintains Sector Perform Rating, Speculative Risk Qualifier

03/16/2022 | 06:42am EDT


© MT Newswires 2022
All news about APREA THERAPEUTICS, INC.
05/25Berenberg Bank Adjusts Aprea Therapeutics' Price Target to $1 From $4, Maintains Hold R..
MT
05/17APREA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acqui..
AQ
05/17APREA THERAPEUTICS, INC.(NASDAQGS : APRE) added to NASDAQ Composite Index
CI
05/16APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
05/16TRANSCRIPT : Aprea Therapeutics, Inc. - Special Call
CI
05/16APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Di..
AQ
05/16Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports Firs..
GL
05/16Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/16Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/16ATRIN PHARMACEUTICALS LLC ACQUIRED A : APRE) in a reverse merger transaction.
CI
More news
Analyst Recommendations on APREA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021
Net income 2021
Net Debt 2021
P/E ratio 2021
Yield 2021
Capitalization 18,7 M 18,7 M -
EV / Sales 2021
EV / Sales 2022 -
Nbr of Employees -
Free-Float 90,2%
Chart APREA THERAPEUTICS, INC.
Duration : Period :
Aprea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APREA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 0,81 $
Average target price 1,00 $
Spread / Average Target 23,5%
EPS Revisions
Managers and Directors
Christian S. Schade Chairman & Chief Executive Officer
Oren Gilad President & Director
Scott M. Coiante Chief Financial Officer, Secretary & Senior VP
Eyal C. Attar Chief Medical Officer & Senior Vice President
Lars Abrahmsén Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
APREA THERAPEUTICS, INC.-71.78%19
MODERNA, INC.-44.02%57 385
IQVIA HOLDINGS INC.-24.79%40 468
LONZA GROUP AG-32.64%39 851
SEAGEN INC.15.44%33 010
CELLTRION, INC.-11.87%18 371